In addition, in biologically aggressive human tumors, overexpressed USP2a interacts with and stabilizes fatty acid synthase (FAS) (5, 8, 9), which is now recognized as a potentially therapeutic target in cancers of the breast, colon, endometrium, ovary, prostate, and thyroid (10–15). This evidence concerns the gene FASN and cancer.